Tolerability Study of the Application of a 3M Microstructure Transdermal System

Sponsor
Northwestern University (Other)
Overall Status
Completed
CT.gov ID
NCT01257763
Collaborator
3M (Industry)
54
1
2
11
4.9

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the safety and tolerability of an experimental device that introduces microscopic channels into the skin. Creating microscopic channels in the skin allows for better absorption of various medications applied to the skin, and this study will determine if the study device offers a tolerable method by which to introduce these holes. The study population will include 54 individuals, ages 18-74 years old, with a roughly equal distribution of skin colors. Each subject will have a total of three visits 24 hours apart from one another. The study device will be applied at the Baseline and Day 1 visits. At various timepoints before and after device application, skin assessments for irritation will be completed using a 7-point Skin Reaction Scale and photographs will be taken. Subjects will report pain associated with device application using a standardized pain scale. At the baseline visit, a member of the research staff will administer applications of the study device on the side of the subject's forehead, temple and the area below and to the side of the nose on randomly selected sides of the face. The side of the face at each location not receiving application of the study device will receive applications of a "dummy" device. Subjects will not be informed of which device is the study device and which is the "dummy" device. At the Day 1 visit, a member of the research staff will administer study device applications to the center of the subject's forehead. The subject will also self-apply the study device to the chin, under the instruction of the research staff member. At the Day 2 visit, final skin assessments will be made and the subject will be evaluated and treated for any persistent skin irritation. Differences in skin irritation between sites of study device application and "dummy" device application will be determined, as well as several other endpoints.

Condition or Disease Intervention/Treatment Phase
  • Device: Transdermal Microchannel Skin System
  • Device: Sham device
Phase 1

Study Design

Study Type:
Interventional
Actual Enrollment :
54 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Other
Official Title:
Tolerability Study of the Application of a 3M Microstructure Transdermal System by Finger Pressure to the Face in Healthy Subjects Stratified by Age and Fitzpatrick Skin Type
Study Start Date :
May 1, 2010
Actual Primary Completion Date :
Apr 1, 2011
Actual Study Completion Date :
Apr 1, 2011

Arms and Interventions

Arm Intervention/Treatment
Experimental: Study device

The study device is a transdermal microneedle array designed to introduce microscopic channels into the skin. The study device arm will receive application of this device.

Device: Transdermal Microchannel Skin System
A member of the research staff will apply the study device to the subject's lateral forehead, temple and nasolabial area on randomly selected sides of the face, 3 times at each anatomical location, for a total of 9 applications. All subjects will also receive 9 adjacent applications to the central forehead, and they will self-administer 3 adjacent applications to the chin under instruction of study staff.

Sham Comparator: Sham device

The sham device will be very similar in appearance to the study device. The sham device arm will receive application of this device.

Device: Sham device
The side not receiving application of the study device at each anatomical location will receive a comparable number of applications of a sham device.

Outcome Measures

Primary Outcome Measures

  1. Local skin reaction scores [48 hours]

    Difference in median local skin reaction scores between Study Device side and Control side for any of the three facial application sites at any of the seven follow-up times.

  2. Median pain scores [5 minutes]

    Difference in median pain scores between Study Device side and Control side for any of the three facial application sites.

  3. Local skin reaction and reported pain central forehead [24 hours]

    Reported pain and change in skin irritation at the central forehead site.

  4. Local skin reaction score and reported pain chin [24 hours]

    Reported pain and change in skin irritation at the chin site.

Secondary Outcome Measures

  1. Max difference in skin reaction score [48 hours]

    Maximal difference in local skin reaction score at any follow-up visit

  2. Subject questionnaire differences [48 hours]

    Reported differences in skin irritation or side-effects reported per patient questionnaire

  3. Differences between skin type groupings [48 hours]

    Differences in reported pain or changes in local skin reaction score at central forehead site between the 3 Fitzpatrick skin type groupings (I-II, III-IV and V-VI).

  4. Differences between age groups [48 hours]

    Differences in reported pain or changes in local skin reaction score at central forehead site between 3 age groupings (18-35, 36-60, 61-74).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 74 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Age 18-74 years old

  • Subject in good health as determined by the investigator

  • Subject has the willingness and the ability to understand and provide informed consent and communicate with the investigator

Exclusion Criteria:
  • Subjects with active systemic or skin disease (including acne) or skin infection that could, in the opinion of the investigator, interfere with accurate study assessments

  • Baseline skin irritation as defined by a local skin reaction score greater than "0" at any of the application areas (Appendix 1)

  • Facial cosmetic procedures performed within 4 weeks of the baseline visit that may, in the opinion of the investigator, have an impact on skin assessment results†

  • Topical medications applied to the face within 2 weeks of the baseline visit that may, in the opinion of the investigator, have an impact on skin assessment results†

  • Subjects with skin disease such as atopic dermatitis, urticaria or dermatographism that may be exacerbated by device application †Subjects may enroll after a corresponding washout period

Contacts and Locations

Locations

Site City State Country Postal Code
1 Northwestern University Feinberg School of Medicine, Department of Dermatology Chicago Illinois United States 60611

Sponsors and Collaborators

  • Northwestern University
  • 3M

Investigators

  • Study Director: Dennis P West, PhD, Northwestern University
  • Principal Investigator: Murad Alam, MD, Northwestern University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Murad Alam, Professor in Dermatology, Otolaryngology- Head and Neck Surgery, and Surgery-Organ Transplantation, Northwestern University
ClinicalTrials.gov Identifier:
NCT01257763
Other Study ID Numbers:
  • STU38370
First Posted:
Dec 10, 2010
Last Update Posted:
Dec 2, 2021
Last Verified:
Nov 1, 2021
Keywords provided by Murad Alam, Professor in Dermatology, Otolaryngology- Head and Neck Surgery, and Surgery-Organ Transplantation, Northwestern University

Study Results

No Results Posted as of Dec 2, 2021